JP2022525914A - 感染性心内膜炎を治療する方法 - Google Patents

感染性心内膜炎を治療する方法 Download PDF

Info

Publication number
JP2022525914A
JP2022525914A JP2021556394A JP2021556394A JP2022525914A JP 2022525914 A JP2022525914 A JP 2022525914A JP 2021556394 A JP2021556394 A JP 2021556394A JP 2021556394 A JP2021556394 A JP 2021556394A JP 2022525914 A JP2022525914 A JP 2022525914A
Authority
JP
Japan
Prior art keywords
gram
antibiotics
lysate
dose
plyss2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525914A5 (https=
Inventor
レイモンド シューフ
Original Assignee
コントラフェクト コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コントラフェクト コーポレイション filed Critical コントラフェクト コーポレイション
Publication of JP2022525914A publication Critical patent/JP2022525914A/ja
Publication of JP2022525914A5 publication Critical patent/JP2022525914A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021556394A 2019-03-22 2020-03-20 感染性心内膜炎を治療する方法 Pending JP2022525914A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962822386P 2019-03-22 2019-03-22
US62/822,386 2019-03-22
US201962832708P 2019-04-11 2019-04-11
US62/832,708 2019-04-11
US201962849093P 2019-05-16 2019-05-16
US62/849,093 2019-05-16
US201962898379P 2019-09-10 2019-09-10
US62/898,379 2019-09-10
US202062965720P 2020-01-24 2020-01-24
US62/965,720 2020-01-24
PCT/US2020/024051 WO2020198073A1 (en) 2019-03-22 2020-03-20 Method of treating infective endocarditis

Publications (2)

Publication Number Publication Date
JP2022525914A true JP2022525914A (ja) 2022-05-20
JP2022525914A5 JP2022525914A5 (https=) 2023-03-16

Family

ID=72611751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556394A Pending JP2022525914A (ja) 2019-03-22 2020-03-20 感染性心内膜炎を治療する方法

Country Status (11)

Country Link
US (1) US20220160842A1 (https=)
EP (1) EP3941504A4 (https=)
JP (1) JP2022525914A (https=)
KR (1) KR20210141667A (https=)
CN (1) CN114025782A (https=)
AU (1) AU2020244764A1 (https=)
BR (1) BR112021018219A2 (https=)
CA (1) CA3134154A1 (https=)
IL (1) IL286389A (https=)
MX (1) MX2021011469A (https=)
WO (1) WO2020198073A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023560A1 (en) * 2021-08-17 2023-02-23 Contrafect Corporation New uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511698A (ja) * 2006-12-08 2010-04-15 ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション 退行性疾患及び炎症性疾患に対する予防および治療の効果を有する７−ヒドロキシ−６−メトキシ−１，２，３，４−テトラヒドロイソキノリン誘導体
JP2015521178A (ja) * 2012-05-09 2015-07-27 コントラフェクト コーポレイション バクテリオファージ溶解素によるバイオフィルムの防止、破壊および処置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP2699689A4 (en) * 2011-04-21 2014-12-17 Univ Utrecht Holding Bv STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES
KR20210121313A (ko) * 2012-05-09 2021-10-07 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
AU2016324307B2 (en) * 2015-09-17 2021-10-21 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
KR20190004799A (ko) * 2016-05-12 2019-01-14 콘트라펙트 코포레이션 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법
CA3069679A1 (en) * 2017-07-10 2019-01-17 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511698A (ja) * 2006-12-08 2010-04-15 ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション 退行性疾患及び炎症性疾患に対する予防および治療の効果を有する７−ヒドロキシ−６−メトキシ−１，２，３，４−テトラヒドロイソキノリン誘導体
JP2015521178A (ja) * 2012-05-09 2015-07-27 コントラフェクト コーポレイション バクテリオファージ溶解素によるバイオフィルムの防止、破壊および処置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J INFECT DIS, vol. 209, no. 9, JPN6024007950, 2014, pages 1469 - 1478, ISSN: 0005426215 *

Also Published As

Publication number Publication date
KR20210141667A (ko) 2021-11-23
EP3941504A4 (en) 2022-12-07
IL286389A (en) 2021-10-31
EP3941504A1 (en) 2022-01-26
US20220160842A1 (en) 2022-05-26
WO2020198073A1 (en) 2020-10-01
BR112021018219A2 (pt) 2022-01-18
AU2020244764A1 (en) 2021-10-14
MX2021011469A (es) 2021-10-22
CA3134154A1 (en) 2020-10-01
CN114025782A (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
US12144845B2 (en) Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
KR102084388B1 (ko) 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR102310387B1 (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
Song et al. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model
KR20010022237A (ko) 리소스타핀을 단독 또는 항생제와의 조합으로 포함하는포도상구균 감염 치료용 약제학적 조성물
CN1353602A (zh) 治疗葡萄球菌感染的组合物和方法
CN112218659A (zh) 用于治疗葡萄球菌感染的治疗性噬菌体组合物
US20210260070A1 (en) Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporins
CN102481369A (zh) 抗革兰氏阴性菌剂
JP2022525914A (ja) 感染性心内膜炎を治療する方法
US20220193186A1 (en) Method of treating and preventing bone and joint infections
KR20150038611A (ko) 백본-고리형 펩타이드와의 조합물
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
US20230263865A1 (en) Compositions and methods comprising lysin plycp025 and derivatives thereof
WO2022261360A1 (en) Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115209912A (zh) 肽组合物及其使用方法
CN107835686A (zh) 抗菌组合物
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾ＰｌｙＳｓ２溶解素及び抗生物質の組合せ
Abraham et al. 1 A tick antivirulence protein potentiates antibiotics against Staphylococcus aureus 2
PL166731B1 (pl) Sposób wytwarzania środka do leczenia infekcji wywołanych przez organizmy wrażliwe na antybiotykiβ-laktamowe

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001